ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cellino Biotech, a Massachusetts-based cell therapy manufacturer, has closed an $80 million series A financing round led by firms including the venture arm of Bayer. Cellino, which employs artificial intelligence and laser technology in an automated platform, seeks to reduce the cost of producing stem cell–derived therapies. Proceeds from the financing will go toward developing software, machine learning, and hardware elements of Cellino’s platform for making autologous and allogeneic stem cells.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter